{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:59:17Z","timestamp":1794005957436,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dietary advanced glycation end products(AGEs) may contribute to increased inflammation and oxidative stress as risk factors for chronic diseases such as liver disease. In the current study, we aimed to examine the possible association of dietary AGEs with the odds of non-alcoholic fatty liver disease (NAFLD) in Iranian adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 675 participants (225 newly diagnosed NAFLD cases and 450 controls), aged\u2009\u200920\u201360 years, were recruited for this case-control study. Nutritional data were measured using a validated food frequency questionnaire, and dietary AGEs were determined for all participants. An ultrasound scan of the liver performed the detection of NAFLD in participants of the case group without alcohol consumption and other causes of hepatic disorders. We used logistic regression models, adjusted for potential confounders, to estimate the odds ratios(ORs) and 95% confidence interval(CI) of NAFLD across tertiles of dietary AGEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean\u2009\u00b1\u2009SD age and body mass index of the participants were 38.13\u2009\u00b1\u20098.85 years and 26.85\u2009\u00b1\u20094.31\u00a0kg\/m<jats:sup>2<\/jats:sup>, respectively. The median(IQR) of dietary AGEs in participants was 3262(2472\u20134301). In the sex and age-adjusted model, the odds of NAFLD were increased across tertiles of dietary AGEs intake(OR:16.48;95%CI:9.57\u201328.40, P<jats:sub>trend<\/jats:sub>&lt;0.001). Also, in the final model, after controlling for confounding effects of BMI, smoking, physical activity, marital status, socio-economic status, and energy intake, the odds of NAFLD were increased across tertiles of dietary AGEs intake(OR:12.16; 95%CI:6.06\u201324.39, P<jats:sub>trend<\/jats:sub>&lt;0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results showed that greater adherence to dietary pattern with high dietary AGEs intake was significantly related to increased odds of NAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-023-01365-8","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T04:01:53Z","timestamp":1684382513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dietary advanced glycation end products are associated with an increased risk of non-alcoholic fatty liver disease in Iranian adults"],"prefix":"10.1186","volume":"23","author":[{"given":"Mitra Kazemi","family":"Jahromi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asal Neshatbini","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Teymoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Daftari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmadirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Salehi-Sahlabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Farhadnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Mirmiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"2","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jceh.2015.02.002","volume":"5","author":"M Sharma","year":"2015","unstructured":"Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol. 2015;5(2):147\u201358.","journal-title":"J Clin Exp Hepatol"},{"issue":"01","key":"1365_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","volume":"134","author":"Y-X Xian","year":"2021","unstructured":"Xian Y-X, Weng J-P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2021;134(01):8\u201319.","journal-title":"Chin Med J"},{"issue":"2","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5009\/gnl20127","volume":"15","author":"S Murag","year":"2021","unstructured":"Murag S, Ahmed A, Kim D. Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver. 2021;15(2):206.","journal-title":"Gut Liver"},{"issue":"4","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"e35143","DOI":"10.1371\/journal.pone.0035143","volume":"7","author":"R Patel","year":"2012","unstructured":"Patel R, Baker SS, Liu W, Desai S, Alkhouri R, Kozielski R, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS ONE. 2012;7(4):e35143.","journal-title":"PLoS ONE"},{"issue":"2","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/1319-3767.178527","volume":"22","author":"A Dajani","year":"2016","unstructured":"Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: where do we stand? An overview. Saudi J gastroenterology: official J Saudi Gastroenterol Association. 2016;22(2):91.","journal-title":"Saudi J gastroenterology: official J Saudi Gastroenterol Association"},{"key":"1365_CR6","doi-asserted-by":"crossref","unstructured":"Fernando DH, Forbes JM, Angus PW, Herath CB. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int J Mol Sci. 2019;20(20).","DOI":"10.3390\/ijms20205037"},{"issue":"4","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"J-G Fan","year":"2017","unstructured":"Fan J-G, Kim S-U, Wong VW-S. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"1","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000282080","volume":"28","author":"S Bellentani","year":"2010","unstructured":"Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155\u201361.","journal-title":"Dig Dis"},{"issue":"1","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.dsx.2018.09.002","volume":"13","author":"HMM Herath","year":"2019","unstructured":"Herath HMM, Kodikara I, Weerarathna TP, Liyanage G. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in sri lankan patients with type 2 diabetes: a single center study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):246\u201350.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"1365_CR10","doi-asserted-by":"crossref","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology; 2022.","DOI":"10.1016\/S2468-1253(22)00165-0"},{"issue":"9","key":"1365_CR11","first-page":"1275","volume":"43","author":"B Amirkalali","year":"2014","unstructured":"Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J public health. 2014;43(9):1275.","journal-title":"Iran J public health"},{"issue":"29","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.3748\/wjg.v17.i29.3377","volume":"17","author":"S Zelber-Sagi","year":"2011","unstructured":"Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377\u201389.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1365_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.dsx.2018.01.001","volume":"12","author":"S Vanjiappan","year":"2018","unstructured":"Vanjiappan S, Hamide A, Ananthakrishnan R, Periyasamy SG, Mehalingam V. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018;12(4):479\u201382.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"issue":"2","key":"1365_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","volume":"66","author":"J Ma","year":"2017","unstructured":"Ma J, Hwang S-J, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390\u20137.","journal-title":"J Hepatol"},{"issue":"3","key":"1365_CR15","doi-asserted-by":"publisher","first-page":"e0174291","DOI":"10.1371\/journal.pone.0174291","volume":"12","author":"Y Li","year":"2017","unstructured":"Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS ONE. 2017;12(3):e0174291.","journal-title":"PLoS ONE"},{"issue":"6","key":"1365_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jhep.2018.01.015","volume":"68","author":"S Zelber-Sagi","year":"2018","unstructured":"Zelber-Sagi S, Ivancovsky-Wajcman D, Isakov NF, Webb M, Orenstein D, Shibolet O, et al. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol. 2018;68(6):1239\u201346.","journal-title":"J Hepatol"},{"key":"1365_CR17","doi-asserted-by":"crossref","unstructured":"Emamat H, Farhadnejad H, Movahedian M, Tangestani H, Mirmiran P, Hekmatdoost A. Dietary sodium intake in relation to non-alcoholic fatty liver disease risk: a case-control study. Nutrition & Food Science; 2020.","DOI":"10.1108\/NFS-05-2020-0183"},{"key":"1365_CR18","doi-asserted-by":"crossref","unstructured":"Emamat H, Farhadnejad H, Poustchi H, Hekmatdoost A. Galactose intake is related to nonalcoholic fatty liver disease. Nutrition & Food Science; 2018.","DOI":"10.1108\/NFS-06-2018-0174"},{"issue":"3","key":"1365_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/nu8030125","volume":"8","author":"RE Clarke","year":"2016","unstructured":"Clarke RE, Dordevic AL, Tan SM, Ryan L, Coughlan MT. Dietary advanced glycation end products and risk factors for chronic disease: a systematic review of randomised controlled trials. Nutrients. 2016;8(3):125.","journal-title":"Nutrients"},{"key":"1365_CR20","doi-asserted-by":"publisher","first-page":"3818196","DOI":"10.1155\/2020\/3818196","volume":"2020","author":"A Perrone","year":"2020","unstructured":"Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev. 2020;2020:3818196.","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"1365_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/br.2021.1422","volume":"14","author":"A Kuzan","year":"2021","unstructured":"Kuzan A. Toxicity of advanced glycation end products (review). Biomed Rep. 2021;14(5):46.","journal-title":"Biomed Rep"},{"issue":"8","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jada.2004.05.214","volume":"104","author":"T Goldberg","year":"2004","unstructured":"Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104(8):1287\u201391.","journal-title":"J Am Diet Assoc"},{"key":"1365_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/jrms.JRMS_982_17","volume":"23","author":"P Mirmiran","year":"2018","unstructured":"Mirmiran P, Yousefi R, Mottaghi A, Azizi F. Advanced glycation end products and risk of hypertension in iranian adults: Tehran lipid and glucose study. J Res Med sciences: official J Isfahan Univ Med Sci. 2018;23:43.","journal-title":"J Res Med sciences: official J Isfahan Univ Med Sci"},{"key":"1365_CR24","doi-asserted-by":"crossref","unstructured":"Mendoza-Herrera K, Aradillas-Garc\u00eda C, Mej\u00eda-Diaz MA. Association of Dietary Advanced Glycation End Products with Metabolic Syndrome in Young Mexican Adults. 2018;5(4).","DOI":"10.3390\/medicines5040128"},{"issue":"2","key":"1365_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s12276-021-00561-7","volume":"53","author":"W Rungratanawanich","year":"2021","unstructured":"Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 2021;53(2):168\u201388.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1365_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14711-3","volume":"7","author":"A Sakasai-Sakai","year":"2017","unstructured":"Sakasai-Sakai A, Takata T, Takino J-i, Takeuchi M. Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death. Sci Rep. 2017;7(1):1\u201311.","journal-title":"Sci Rep"},{"issue":"3","key":"1365_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jhep.2011.07.028","volume":"56","author":"KH Gaens","year":"2012","unstructured":"Gaens KH, Niessen PM, Rensen SS, Buurman WA, Greve JWM, Driessen A, et al. Endogenous formation of N\u03b5-(carboxymethyl) lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol. 2012;56(3):647\u201355.","journal-title":"J Hepatol"},{"issue":"3","key":"1365_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/ajcn\/85.3.910","volume":"85","author":"A Esmaillzadeh","year":"2007","unstructured":"Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns, insulin resistance, and prevalence of the metabolic syndrome in women. Am J Clin Nutr. 2007;85(3):910\u20138.","journal-title":"Am J Clin Nutr"},{"issue":"213","key":"1365_CR29","first-page":"42","volume":"7","author":"M Ghaffarpour","year":"1999","unstructured":"Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran: Nashre Olume Keshavarzy. 1999;7(213):42\u201358.","journal-title":"Tehran: Nashre Olume Keshavarzy"},{"key":"1365_CR30","unstructured":"Bowman SA, Friday JE, Moshfegh AJ. MyPyramid equivalents database, 2.0 for USDA survey foods, 2003\u20132004: documentation and user guide. US Department of Agriculture; 2008."},{"key":"1365_CR31","volume-title":"Food composition table of Iran","author":"M Azar","year":"1980","unstructured":"Azar M. In: Sarkisian E, editor. Food composition table of Iran. Volume 65. Tehran: National Nutrition and Food Research Institute, Shaheed Beheshti University; 1980."},{"issue":"6","key":"1365_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jada.2010.03.018","volume":"110","author":"J Uribarri","year":"2010","unstructured":"Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911\u201316e12.","journal-title":"J Am Diet Assoc"},{"issue":"8","key":"1365_CR33","first-page":"1073","volume":"18","author":"MB Moghaddam","year":"2012","unstructured":"Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The iranian version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073\u201380.","journal-title":"World Appl Sci J"},{"issue":"9","key":"1365_CR34","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1097\/00005768-200009001-00009","volume":"32","author":"BE Ainsworth","year":"2000","unstructured":"Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9):S498\u2013S504.","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"1365_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5868-8-115","volume":"8","author":"PH Lee","year":"2011","unstructured":"Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys activity. 2011;8(1):1\u201311.","journal-title":"Int J Behav Nutr Phys activity"},{"issue":"2","key":"1365_CR36","first-page":"137","volume":"9","author":"GR Garmaroudi","year":"2010","unstructured":"Garmaroudi GR, Moradi A. Socio-economic status in Iran: a study of measurement index. Payesh (Health Monitor). 2010;9(2):137\u201344.","journal-title":"Payesh (Health Monitor)"},{"issue":"1","key":"1365_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40200-016-0247-5","volume":"15","author":"P Mirmiran","year":"2015","unstructured":"Mirmiran P, Esfandiari S, Bahadoran Z, Tohidi M, Azizi F. Dietary insulin load and insulin index are associated with the risk of insulin resistance: a prospective approach in tehran lipid and glucose study. J Diabetes Metabolic Disorders. 2015;15(1):1\u20137.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"1","key":"1365_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12937-023-00834-z","volume":"22","author":"P Mirmiran","year":"2023","unstructured":"Mirmiran P, Teymoori F, Farhadnejad H, Mokhtari E, Salehi-Sahlabadi A. Nitrate containing vegetables and dietary nitrate and nonalcoholic fatty liver disease: a case control study. Nutr J. 2023;22(1):3.","journal-title":"Nutr J"},{"issue":"8","key":"1365_CR39","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/cas.15455","volume":"113","author":"K Wada","year":"2022","unstructured":"Wada K, Nakashima Y, Yamakawa M, Hori A, Seishima M, Tanabashi S, et al. Dietary advanced glycation end products and cancer risk in Japan: from the Takayama study. Cancer Sci. 2022;113(8):2839\u201348.","journal-title":"Cancer Sci"},{"issue":"2","key":"1365_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/jgh.12042","volume":"28","author":"M Goodwin","year":"2013","unstructured":"Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, et al. Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol. 2013;28(2):369\u201376.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1365_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jhep.2013.11.033","volume":"60","author":"C Leung","year":"2014","unstructured":"Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol. 2014;60(4):832\u20138.","journal-title":"J Hepatol"},{"issue":"35","key":"1365_CR42","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.3748\/wjg.v22.i35.8026","volume":"22","author":"C Leung","year":"2016","unstructured":"Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, et al. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease. World J Gastroenterol. 2016;22(35):8026\u201340.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1365_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1872-034X.2011.00849.x","volume":"41","author":"H Hyogo","year":"2011","unstructured":"Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41(11):1057\u201365.","journal-title":"Hepatol Res"},{"issue":"29","key":"1365_CR44","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.3748\/wjg.v27.i29.4913","volume":"27","author":"E Pereira","year":"2021","unstructured":"Pereira E, Paula DP, de Araujo BP, da Fonseca MJM, Diniz M, Daliry A, et al. Advanced glycation end product: a potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol. 2021;27(29):4913\u201328.","journal-title":"World J Gastroenterol"},{"key":"1365_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.metabol.2018.01.023","volume":"83","author":"SA Palma-Duran","year":"2018","unstructured":"Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, et al. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120\u20137.","journal-title":"Metabolism"},{"key":"1365_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.nutres.2022.04.005","volume":"104","author":"K Priken","year":"2022","unstructured":"Priken K, Tapia G, Cadagan C, Quezada N, Torres J, D\u2019Espessailles A, et al. Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis. Nutr Res. 2022;104:71\u201381.","journal-title":"Nutr Res"},{"issue":"1","key":"1365_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y","volume":"81","author":"JS Huang","year":"2001","unstructured":"Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK\/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001;81(1):102\u201313.","journal-title":"J Cell Biochem"},{"issue":"4","key":"1365_CR48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00535-007-2152-7","volume":"43","author":"K Iwamoto","year":"2008","unstructured":"Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43(4):298\u2013304.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1365_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/hep.21093","volume":"43","author":"SS Zhan","year":"2006","unstructured":"Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43(3):435\u201343.","journal-title":"Hepatology"},{"issue":"5","key":"1365_CR50","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1172\/JCI118889","volume":"98","author":"T Miyata","year":"1996","unstructured":"Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest. 1996;98(5):1088\u201394.","journal-title":"J Clin Invest"},{"issue":"2","key":"1365_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","volume":"14","author":"F Marra","year":"2008","unstructured":"Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72\u201381.","journal-title":"Trends Mol Med"},{"issue":"6","key":"1365_CR52","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.21655","volume":"45","author":"K Yamaguchi","year":"2007","unstructured":"Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366\u201374.","journal-title":"Hepatology"},{"issue":"2","key":"1365_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2796.2002.00932.x","volume":"251","author":"H Vlassara","year":"2002","unstructured":"Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87\u2013101.","journal-title":"J Intern Med"},{"key":"1365_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1749-6632.2002.tb02107.x","volume":"959","author":"JW Baynes","year":"2002","unstructured":"Baynes JW. The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci. 2002;959:360\u20137.","journal-title":"Ann N Y Acad Sci"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01365-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:01:57Z","timestamp":1684386117000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01365-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01365-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"20 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from participants. All procedures performed in studies involving human participants adhered to the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics committee of Isfahan University of Medical Sciences, Isfahan, Iran.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}